BruceA.CreeMD
Neurology • San Francisco, CANeuroimmunology/Multiple Sclerosis
Associate Clinical Professor, Neurology, UCSF School of Medicine
Dr. Cree is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Owens St, Suite 320
San Francisco, CA 94158Phone+1 415-353-2069Fax+1 415-353-2633
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
University of California San Francisco School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2001 - 2026- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety and Tolerability of Rituximab in Neuromyelitis Optica Start of enrollment: 2004 Jan 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.Sven G Meuth, Stephanie Wolff, Anna Mück, Alice Willison, Konstanze Kleinschnitz
Annals of Neurology. 2024-11-25 - Incorporation of the central vein sign into the McDonald criteria.Moein Amin, Kunio Nakamura, Lynn Daboul, Carly O'Donnell, Quy Cao
Multiple Sclerosis and Related Disorders. 2024-11-25 - 1 citationsSafety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, pha...Xavier Montalban, Patrick Vermersch, Douglas L Arnold, Amit Bar-Or, Bruce A C Cree
The Lancet. Neurology. 2024-11-01
Lectures
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Denver, Colorado - 4/20/2013
- Join now to see all
Press Mentions
Smoldering MS May Warrant Unique Diagnosis, Treatment, and Research StrategiesNovember 7th, 2024- How Progressive Multiple Sclerosis Differs from Relapsing-Remitting MSAugust 27th, 2024
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDMarch 15th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
